AbbVie Inc. (NYSE:ABBV)

The income tax expense (benefit) exhibited considerable fluctuation over the five-year period. Current taxes generally increased from 2021 to 2023, while deferred taxes consistently represented a negative adjustment, growing in magnitude before decreasing significantly in the later years. The interplay between these two components resulted in a volatile income tax expense (benefit) line.

Current Taxes

Current taxes increased from US$2,338 million in 2021 to US$3,563 million in 2022, representing a substantial rise. This growth continued into 2023, reaching US$4,266 million. However, a significant decrease was observed in 2024, falling to US$879 million, before partially recovering to US$2,856 million in 2025. This suggests potential changes in taxable income or applicable tax rates.

Deferred Taxes

Deferred taxes consistently represented a tax benefit, indicated by negative values. The magnitude of this benefit increased from US$-898 million in 2021 to US$-1,931 million in 2022, and further to US$-2,889 million in 2023. This trend reversed in 2024, with the benefit decreasing to US$-1,449 million, and continued to diminish in 2025, reaching US$-492 million. This shift could be attributed to changes in temporary differences between book and tax bases of assets and liabilities.

Income Tax Expense (Benefit)

The income tax expense (benefit) was positive in 2021, 2022, and 2023, at US$1,440 million, US$1,632 million, and US$1,377 million respectively, indicating a net tax expense. A significant shift occurred in 2024, resulting in a net tax benefit of US$-570 million. This trend continued into 2025, with a substantial positive swing to a tax expense of US$2,364 million. The volatility in this line item highlights the significant impact of deferred tax adjustments and fluctuations in current tax liabilities.

The substantial decrease in current taxes in 2024, coupled with the diminishing deferred tax benefit, contributed to the net tax benefit observed in that year. The subsequent reversal of these trends in 2025 resulted in a significant increase in income tax expense. Further investigation into the underlying drivers of these changes, such as changes in profitability, tax legislation, and the utilization of tax loss carryforwards, would be beneficial.

The effective income tax rate exhibits significant fluctuations over the observed period. While the statutory tax rate remained constant at 21.00%, the effective tax rate demonstrates considerable variance, indicating factors beyond the standard corporate tax obligations are influencing AbbVie’s tax burden.

Effective Tax Rate Trend

In 2021, the effective tax rate was 11.10%, increasing to 12.10% in 2022. A substantial rise is then observed in 2023, with the effective tax rate reaching 22.00%, approaching the statutory rate. However, 2024 shows a markedly negative effective tax rate of -15.30%, followed by a significant positive swing to 35.80% in 2025.

The deviation of the effective tax rate from the statutory rate suggests the presence of tax benefits, deductions, or credits in 2021 and 2022, reducing the overall tax liability. The increase in 2023 could indicate a reduction in these benefits or a change in the mix of income sources. The negative effective tax rate in 2024 is particularly noteworthy, implying tax benefits exceeded the tax liability, potentially due to items such as tax credits, deferred tax asset realizations, or changes in tax laws. The substantial increase to 35.80% in 2025 suggests a reversal of these benefits or a shift in taxable income composition.

Potential Drivers of Fluctuations

The volatility in the effective tax rate warrants further investigation into the specific components driving these changes. Potential factors include geographic earnings mix, research and development tax credits, changes in deferred tax assets and liabilities, and the impact of tax legislation. The negative rate in 2024 is an anomaly that requires detailed explanation.

Continued monitoring of the effective tax rate is recommended, alongside a thorough understanding of the underlying factors contributing to its fluctuations, to assess potential impacts on future financial performance and tax planning strategies.

The composition of deferred tax assets and liabilities exhibits notable shifts over the five-year period. A significant increase in deferred tax assets is observed, driven primarily by growth in net operating loss carryforwards and accruals and reserves, though partially offset by a rising valuation allowance. Deferred tax liabilities demonstrate a consistent decrease, primarily attributable to a reduction in the excess of book basis over tax basis of intangible assets.

Deferred Tax Assets - Composition

Net operating loss and other carryforwards represent the largest component of deferred tax assets, increasing substantially from US$10,095 million in 2021 to US$16,022 million in 2025. Compensation and employee benefits show a marked decrease, falling from US$937 million to US$74 million over the same period. Accruals and reserves demonstrate a general upward trend, increasing from US$667 million to US$1,133 million. Chargebacks and rebates also increased, moving from US$837 million to US$1,482 million. Other deferred tax assets show moderate growth. The valuation allowance against deferred tax assets has increased consistently, rising from US$9,391 million to US$15,018 million, indicating increasing uncertainty regarding the realization of these assets.

Deferred Tax Liabilities - Composition

The primary driver of deferred tax liabilities is the excess of book basis over tax basis of intangible assets, which decreased significantly from US$4,711 million in 2021 to US$1,530 million in 2025. The excess of book basis over tax basis in investments also decreased, though to a lesser extent, moving from US$308 million to US$322 million. Other deferred tax liabilities show a consistent, albeit moderate, decline.

Net Deferred Tax Assets (Liabilities)

The net deferred tax position transitioned from a net liability of US$735 million in 2021 to a net asset of US$3,715 million in 2025. This shift is attributable to the greater increase in deferred tax assets compared to the decrease in deferred tax liabilities. The net position peaked at US$3,803 million in 2023 before experiencing a slight decrease in 2024, followed by a further increase in 2025.

The increasing valuation allowance against deferred tax assets warrants attention, as it suggests a growing concern about the future tax benefits associated with these assets. The substantial decline in deferred tax liabilities, particularly related to intangible assets, may reflect changes in the company’s asset base or tax planning strategies. Overall, the trend indicates a strengthening net deferred tax asset position.

The deferred tax asset balance exhibited a consistent upward trend over the five-year period. Conversely, the deferred tax liability balance demonstrated more fluctuation, initially decreasing before increasing in later years. A notable shift occurred between 2021 and 2022, and again between 2022 and 2023, impacting the net deferred tax position.

Deferred Tax Assets

The deferred tax asset balance increased from US$2,274 million in 2021 to US$6,104 million in 2025. The most significant increase occurred between 2022 and 2023, rising from US$3,020 million to US$5,755 million. Growth continued, albeit at a slower pace, in 2024 and 2025. This sustained increase suggests a growing expectation of future taxable income against which these assets can be realized, or the recognition of new deductible temporary differences.

Deferred Tax Liabilities

The deferred tax liability balance decreased from US$3,009 million in 2021 to US$1,952 million in 2023. However, it then increased to US$2,579 million in 2024 and further to US$2,389 million in 2025. The initial decline may indicate a reduction in taxable temporary differences or changes in applicable tax rates. The subsequent increases could be attributed to the recognition of new taxable temporary differences or adjustments to existing liabilities.

Net Deferred Tax Position

In 2021, the deferred tax liabilities exceeded the deferred tax assets by US$735 million. This net liability position shifted to a net asset of US$830 million by 2022, and expanded to US$3,803 million by 2023. While the net asset position decreased in 2024 to US$3,047 million, it remained positive in 2025 at US$3,715 million. This indicates a strengthening ability to utilize future tax benefits.

The changes in both deferred tax assets and liabilities warrant further investigation to understand the underlying causes, such as changes in tax laws, accounting methods, or business operations. The significant increase in deferred tax assets, coupled with the fluctuating deferred tax liabilities, suggests a dynamic tax position that requires ongoing monitoring.

The financial information reveals a consistent pattern of adjustments related to income taxes, specifically through the removal of deferred tax assets and liabilities. These adjustments impact reported financial statement figures, leading to differences between reported and adjusted values for total assets, total liabilities, and stockholders’ equity. A general trend indicates a decreasing impact of these adjustments over the observed period, though with some fluctuations.

Total Assets

Reported total assets decreased from $146,529 million in 2021 to $133,960 million in 2025. The adjusted total assets show a similar decreasing trend, starting at $144,255 million in 2021 and ending at $127,856 million in 2025. The difference between reported and adjusted assets narrowed from $2,274 million in 2021 to $6,104 million in 2025, suggesting a diminishing effect of deferred tax adjustments on the overall asset base.

Total Liabilities

Reported total liabilities exhibited volatility, decreasing from $131,093 million in 2021 to $121,518 million in 2022, then increasing to $137,188 million in 2025. Adjusted total liabilities followed a similar pattern, moving from $128,084 million in 2021 to $134,799 million in 2025. The gap between reported and adjusted liabilities decreased from $3,009 million in 2021 to $2,389 million in 2025, indicating a lessening impact of deferred tax adjustments on reported liabilities.

Stockholders’ Equity

Reported stockholders’ equity experienced a significant decline, moving from a positive $15,408 million in 2021 to a negative deficit of -$3,270 million in 2025. Adjusted stockholders’ equity also decreased, but to a lesser extent, from $16,143 million in 2021 to a deficit of -$6,985 million in 2025. The difference between reported and adjusted equity widened considerably over the period, starting at $735 million in 2021 and reaching $3,715 million in 2025. This suggests that the removal of deferred tax items had a growing influence on the reported equity position, particularly in later years.

Net Earnings

Reported net earnings attributable to the company decreased from $11,542 million in 2021 to $4,226 million in 2025. Adjusted net earnings show a more pronounced decrease initially, falling to $1,974 million in 2023, but then increasing to $3,734 million in 2025. The difference between reported and adjusted net earnings was largest in 2023 at $2,889 million, and smallest in 2021 at $900 million. This indicates that the adjustments related to deferred taxes had a substantial impact on reported earnings, especially in 2023, but the impact lessened in 2024 and 2025.

In summary, the adjustments consistently reduce reported asset and liability values, and initially reduce reported net earnings. The magnitude of these adjustments appears to be decreasing for assets and liabilities, but the impact on equity and net earnings shows more variability, with a widening gap in equity and a significant impact on earnings in 2023. The trend suggests a potential shift in the company’s tax position or accounting practices related to deferred taxes.

The financial metrics demonstrate a notable divergence between reported and adjusted values following the removal of deferred tax impacts. This adjustment appears to significantly alter the perception of the company’s profitability and efficiency, particularly in later years. A general trend of declining reported profitability is observed, while the adjusted figures reveal a more complex pattern.

Profitability

Reported net profit margin decreased consistently from 20.54% in 2021 to 6.91% in 2025. However, the adjusted net profit margin, while also declining initially, shows some stabilization and even slight improvement in the later periods. The difference between reported and adjusted net profit margin widens considerably from 2022 onwards, suggesting a growing impact from deferred tax adjustments on reported earnings. The adjusted ROE and ROA also show a similar pattern, with substantial increases in 2024 driven by the adjustment, but remaining lower than the reported values.

Asset Turnover

Reported total asset turnover exhibits a modest increase over the period, moving from 0.38 in 2021 to 0.46 in 2025. The adjusted total asset turnover mirrors this trend, with a similar, albeit slightly higher, increase. The difference between reported and adjusted asset turnover remains relatively small, indicating that deferred taxes have a limited impact on this efficiency metric.

Leverage and Returns

Reported financial leverage increases substantially from 2021 to 2024, peaking at 40.65, before data becomes unavailable. The adjusted financial leverage shows an even more dramatic increase, reaching 465.95 in 2024. This suggests that the removal of deferred tax assets or liabilities significantly inflates the apparent level of financial risk. Consequently, reported ROE and adjusted ROE show a similar pattern of increasing divergence. The adjusted ROE experiences a massive surge in 2024, reaching 1,017.63, while the reported ROE is 128.66. This indicates that the deferred tax adjustments have a disproportionately large effect on the return on equity calculation. The reported ROA declines from 7.88% to 3.15%, while the adjusted ROA shows a more pronounced decrease, falling to 1.53% in 2023 before a slight recovery to 2.92% in 2025.

In summary, the adjustments for deferred taxes appear to substantially alter the financial profile of the company. While reported metrics indicate a declining profitability trend, the adjusted figures suggest a more nuanced picture. The significant increases in adjusted financial leverage and ROE, particularly in 2024, warrant further investigation to understand the underlying drivers and potential implications for the company’s financial health.

A review of the financial information reveals significant fluctuations in reported and adjusted net earnings, consequently impacting net profit margins over the five-year period. Reported net earnings attributable to AbbVie Inc. demonstrate a decline from 2021 through 2023, followed by a modest recovery in 2024 and 2025. However, the adjusted net earnings exhibit a more pronounced volatility, with a substantial decrease in 2023 before showing improvement in subsequent years.

Reported Net Profit Margin

The reported net profit margin experienced a gradual decrease from 20.54% in 2021 to 6.91% in 2025. The most significant drop occurred between 2022 and 2023, falling from 20.39% to 8.95%. While there is a slight increase in 2024 and 2025, the margin remains considerably lower than the levels observed in the earlier years of the period.

Adjusted Net Profit Margin

The adjusted net profit margin mirrors the trend in adjusted net earnings, showing a decline from 18.94% in 2021 to a low of 3.63% in 2023. A notable recovery is observed in 2024, reaching 5.02%, and continuing into 2025 with a margin of 6.11%. The difference between the reported and adjusted margins widens considerably in 2023, indicating a substantial impact from adjustments to net earnings in that year. The adjusted margin, while improving in the later years, does not fully recover to the levels seen in 2021 and 2022.

The divergence between reported and adjusted net earnings and their respective margins suggests the presence of significant non-recurring items or accounting adjustments impacting the company’s financial performance. The substantial decline in both metrics in 2023 warrants further investigation to understand the underlying causes. The subsequent recovery in 2024 and 2025, particularly in the adjusted figures, indicates a potential stabilization or improvement in core business operations, though the margins remain below their initial levels.

An examination of the provided financial information reveals trends in both reported and adjusted total assets, alongside their corresponding turnover ratios, over a five-year period. Reported total assets generally decreased from 2021 to 2023, experienced a slight increase in 2024, and then decreased again in 2025. Adjusted total assets followed a similar pattern, exhibiting a more consistent decline throughout the period.

Reported Total Assets

Reported total assets began at US$146,529 million in 2021, declining to US$134,711 million by 2023. A modest recovery to US$135,161 million occurred in 2024, followed by a further decrease to US$133,960 million in 2025. This suggests a potential strategic shift in asset allocation or disposal of assets.

Adjusted Total Assets

Adjusted total assets demonstrated a more pronounced downward trend, moving from US$144,255 million in 2021 to US$127,856 million in 2025. The adjustments made to arrive at this figure may indicate the exclusion of certain asset types, potentially those considered less productive or subject to specific accounting treatments. The consistent decline suggests a deliberate reduction in the asset base when considering these adjustments.

Reported Total Asset Turnover

The reported total asset turnover ratio fluctuated between 0.38 and 0.46 over the period. It increased from 0.38 in 2021 to 0.42 in 2022, decreased slightly to 0.40 in 2023, increased again to 0.42 in 2024, and then rose to 0.46 in 2025. This indicates a generally improving efficiency in generating revenue from reported assets, particularly in the final year of the observed period.

Adjusted Total Asset Turnover

The adjusted total asset turnover ratio mirrored the trend of the reported ratio, ranging from 0.39 to 0.48. It increased from 0.39 in 2021 to 0.43 in 2022, decreased slightly to 0.42 in 2023, increased again to 0.43 in 2024, and then rose to 0.48 in 2025. The adjusted ratio consistently exceeded the reported ratio, suggesting that the adjustments to total assets result in a more favorable turnover metric. The increase in both ratios in 2025 suggests improved asset utilization efficiency.

In summary, while total assets experienced a general decline, the asset turnover ratios demonstrated an improving trend, particularly in the later years. The difference between reported and adjusted turnover ratios highlights the impact of the asset adjustments on the assessment of operational efficiency.

An examination of the financial information reveals notable shifts in reported and adjusted asset and equity positions between 2021 and 2025. These changes significantly impact calculated financial leverage ratios.

Total Assets

Reported total assets experienced a decline from US$146,529 million in 2021 to US$133,960 million in 2025. While there was a slight increase from 2022 to 2023 and from 2023 to 2024, the overall trend is downward. Adjusted total assets mirrored this pattern, decreasing from US$144,255 million to US$127,856 million over the same period.

Stockholders’ Equity

Reported stockholders’ equity demonstrated substantial volatility. It increased from US$15,408 million in 2021 to US$17,254 million in 2022, then decreased sharply to US$10,360 million in 2023 and further to a deficit of US$3,270 million by 2025. Adjusted stockholders’ equity followed a similar trajectory, though the magnitude of the decline differed, moving from US$16,143 million to a deficit of US$6,985 million in 2025.

Reported Financial Leverage

Reported financial leverage, calculated as total assets divided by stockholders’ equity, increased significantly over the period. Starting at 9.51 in 2021, it rose to 8.04 in 2022, then dramatically increased to 13.00 in 2023 and reached 40.65 in 2024. The ratio was not reported for 2025.

Adjusted Financial Leverage

Adjusted financial leverage exhibited a similar, though more pronounced, upward trend. Beginning at 8.94 in 2021 and 8.27 in 2022, it increased to 19.67 in 2023 and surged to 465.95 in 2024. The ratio was not reported for 2025. The substantial increase in adjusted financial leverage in 2024 is particularly noteworthy, indicating a significant reliance on debt or other forms of financing relative to adjusted equity.

The divergence between reported and adjusted figures suggests potential differences in accounting treatments or the inclusion/exclusion of specific items. The consistent increase in both reported and adjusted financial leverage, particularly the dramatic rise in 2024, warrants further investigation to understand the underlying drivers and potential implications for the organization’s financial risk profile.

The period between 2021 and 2025 demonstrates significant fluctuations in reported and adjusted financial performance. Reported net earnings attributable to AbbVie Inc. decreased substantially from 2021 to 2023, followed by a slight recovery in 2024 and 2025, but remained below the 2021 level. Adjusted net earnings exhibited a similar pattern, with a more pronounced decline in 2023 and a slower recovery in subsequent years. Stockholders’ equity, both reported and adjusted, experienced a marked decrease over the period, culminating in a deficit by 2025 for both measures.

Reported Return on Equity (ROE)

Reported ROE began at 74.91% in 2021, decreased to 68.60% in 2022, and then fell considerably to 46.94% in 2023. A substantial increase was observed in 2024, reaching 128.66%, however, a value for 2025 is not available. This volatility suggests a strong sensitivity to changes in net earnings and stockholders’ equity.

Adjusted Return on Equity (ROE)

Adjusted ROE followed a similar trend, starting at 65.94% in 2021 and declining to 60.31% in 2022, then decreasing significantly to 30.11% in 2023. The most dramatic change occurred in 2024, with Adjusted ROE reaching 1,017.63%. A value for 2025 is not available. The large increase in 2024, coupled with the negative adjusted stockholders’ equity in 2025, warrants further investigation. The substantial difference between reported and adjusted ROE suggests that adjustments are having a material impact on the reported financial performance.

The decline in stockholders’ equity, particularly the move into a deficit position by 2025, is a significant concern. This, combined with the fluctuations in net earnings, has resulted in considerable volatility in both reported and adjusted ROE. The exceptionally high ROE figures in 2024, while seemingly positive, should be examined in the context of the declining equity base and the subsequent deficit in 2025. The absence of 2025 ROE values limits a complete understanding of the recent trend.

The period between 2021 and 2025 demonstrates fluctuating performance in reported and adjusted financial metrics. Reported net earnings attributable to AbbVie Inc. decreased significantly from 2021 to 2023, followed by a slight recovery in 2024 and 2025, remaining below the 2021 level. Adjusted net earnings exhibited a similar pattern, with a substantial decline from 2021 to 2023, and a more pronounced recovery in 2024 and 2025, though still not reaching 2021 levels. Total assets, both reported and adjusted, generally decreased over the five-year period, with relatively small fluctuations between 2023 and 2025.

Reported Return on Assets (ROA)

Reported ROA peaked at 8.53% in 2022 before declining to 3.15% by 2025. This decrease aligns with the reduction in reported net earnings, while total assets also decreased, partially offsetting the impact on ROA. The initial increase in 2022 suggests improved profitability relative to asset base, but subsequent declines indicate diminishing returns.

Adjusted Return on Assets (ROA)

Adjusted ROA experienced a more dramatic decrease, falling from 7.38% in 2021 to a low of 1.53% in 2023. A recovery was observed in 2024 and 2025, reaching 2.92%, but remained significantly below the 2021 and 2022 figures. The substantial drop in adjusted net earnings in 2023, coupled with decreasing adjusted total assets, contributed to this decline. The recovery in 2024 and 2025 is attributable to the increased adjusted net earnings, despite continued declines in adjusted total assets.

The divergence between reported and adjusted ROA suggests the presence of significant non-recurring items or accounting adjustments impacting net earnings. The adjusted figures provide a potentially clearer picture of underlying operational performance, revealing a more substantial decline in profitability relative to assets than indicated by the reported figures. The recovery observed in both reported and adjusted ROA in the later years of the period indicates a potential stabilization or improvement in performance, but further investigation is warranted to understand the sustainability of this trend.

Asset Trends

Both reported and adjusted total assets consistently decreased throughout the period. This contraction in the asset base may be due to asset sales, depreciation, or other factors impacting the company’s investment in resources. The relatively stable asset levels between 2023 and 2025 suggest the rate of asset reduction has slowed.

Overall, the financial performance, as indicated by ROA, experienced a period of decline followed by a partial recovery. The adjusted figures highlight a more pronounced initial downturn and a slower recovery, suggesting the impact of specific adjustments on reported earnings. The decreasing asset base is a consistent trend throughout the period.